salanersen

News

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.